Press Releases Exelixis, Inc.

Equities

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 15/01/2026 am IST			5-day change	1st Jan Change
45.23 ^USD	+2.61%		-2.08%	+3.19%

14/01	Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating	MT
13/01	Exelixis, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 05:15 PM

Press Releases

13/01	Exelixis : 260112 Exelixis JP Morgan 2026 Presentation	PU
12/01	Exelixis : Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026	PU
12/01	Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026	BU
07/01	Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer	BU
07/01	Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026	BU
11/12	Exelixis : 251210 Exelixis 2025 R&D Day Presentation	PU
04/12	Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025	BU
07/11	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November	BU
05/11	Exelixis : 251104 Exelixis Q3 2025 Earnings Presentation With Appendix	PU
05/11	Exelixis: Q3 Earnings Snapshot	AQ
05/11	Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update	BU
28/25/28	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL	PR
23/25/23	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL	PR
22/25/22	Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025	BU
20/25/20	Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet	BU
18/25/18	Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025	BU
13/25/13	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL	PR
04/25/04	EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm	PR
03/25/03	EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm	BU
01/25/01	Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development	AQ
30/25/30	Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development	BU
28/25/28	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September	BU
27/25/27	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL	PR
22/25/22	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL	PR
16/25/16	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Exelixis, Inc. : The cure to cancer?

August 05, 2025 at 07:19 pm IST